CIBACALCIN
LOE ApproachingNDAINJECTIONINJECTABLEPriority Review
Approved
Oct 1986
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
1/8 — Limited
Priority Review
Drug data last refreshed 3d ago · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
CIBACALCIN is an injectable small-molecule pharmaceutical approved in 1986 by Novartis. The specific indication and mechanism of action are not documented in available data, limiting clinical context.
LOE Approaching
Product nearing loss of exclusivity with moderate competitive pressure (30) indicates a defensive brand posture and potential team rightsizing or transition focus.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
Zero linked job openings reflect the product's mature, late-lifecycle stage with limited hiring. Career opportunities are constrained; roles focus on defending market share and managing LOE transition rather than growth initiatives.
Brand ManagerField Sales Representative
Worked on CIBACALCIN at Novartis? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.